MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.96
-0.09
-0.75%
After Hours: 11.96 0 0.00% 17:01 04/03 EDT
OPEN
11.98
PREV CLOSE
12.05
HIGH
12.24
LOW
11.45
VOLUME
660.07K
TURNOVER
--
52 WEEK HIGH
16.96
52 WEEK LOW
7.73
MARKET CAP
711.13M
P/E (TTM)
-5.6548
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CYTK stock price target is 20.83 with a high estimate of 30.00 and a low estimate of 12.00.

EPS

CYTK News

More
  • Edited Transcript of CYTK earnings conference call or presentation 3-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 4d ago
  • Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
  • GlobeNewswire · 5d ago
  • Cytokinetics Q1 EPS $(0.04) Down From $0.15 YoY
  • Benzinga · 5d ago
  • CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC
  • GlobeNewswire · 03/20 21:00

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CYTK

Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, reldesemtiv, and spinal muscular atrophy (SMA), CK-3773274 (CK-274).
More

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.